Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Next 5-Year Strategy Calls for Boost to Japanese“Rising Sun”Seed Development
February 27, 2012
-
REGULATORY PAFSC’s First Committee on Drugs Recommends Approval for Eli Lilly’s Once-Weekly GLP-1 Receptor Agonist
February 27, 2012
-
BUSINESS Diabetes Treatments: Their Development and Market (2)
February 27, 2012
-
BUSINESS Daiichi Sankyo and Terumo Codevelop Intradermal Vaccine
February 24, 2012
-
REGULATORY MEXT to Make Drug Education Compulsory at Junior High Schools from FY2012
February 23, 2012
-
BUSINESS Novo Nordisk President Says “Current Pipeline Most Substantial”
February 22, 2012
-
ORGANIZATION Japan Pharmaceutical Political Association Chairman Kumakura to Focus on Resolving Price Difference
February 21, 2012
-
REGULATORY MHLW Issues Improvement Order to Janssen Pharmaceutical for GMP Violation
February 20, 2012
-
BUSINESS Diabetes Treatments: Their Development and Market
February 20, 2012
-
BUSINESS 6 SGLT-2 Inhibitors in Final Development Stage, Applications Expected in 2013
February 17, 2012
-
BUSINESS Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic Ahead of Competitors
February 16, 2012
-
REGULATORY Over 30 Companies Target Nu-lotan Generic Listing in June, 60% Pricing Rule to Apply
February 15, 2012
-
BUSINESS Dispensing Pharmacies Set to Reopen in Disaster-Hit Areas
February 14, 2012
-
REGULATORY Healthcare Providers, Bill Payers in Face-Off Over Additional Premiums for Generic Name Prescriptions
February 13, 2012
-
BUSINESS Nichi-Iko to Shift Back Priority to Its Own Generics from Transferred Long-Listed Products
February 13, 2012
-
ORGANIZATION NPhA Compiles Draft Proposal for Mutual Understanding to Improve Distribution
February 10, 2012
-
BUSINESS Teijin Aims for ¥400 Billion in Sales in Healthcare by FY2020
February 9, 2012
-
BUSINESS Novartis President Mitani Says Diovan Patent Expiry an “Urgent Issue”
February 8, 2012
-
BUSINESS JCR to Push Joint Development with GSK, Including New Biopharmaceuticals
February 7, 2012
-
BUSINESS US, European Pharmaceutical Companies Supported by Steady Japan Business Growth
February 6, 2012
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…